A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

DRUG: Donidalorsen

Sponsor

Ionis Pharmaceuticals, Inc.